Date:3/18/2013

e in other expenses as compared to 2011 was primarily related to the non-cash transaction costs associated with the Company's reverse merger and financing transactions, including the loss of inducement to encourage investors to exercise their warrants early and to participate in the Company's tender offer.
In connection with its financing transactions, the Company issued warrants to purchase 6,099,195 shares of common stock to the placement agent and warrants to purchase 15,247,987 of common stock to the investors in the financing transactions. The warrants issued to the placement agent and the investors were determined to be derivative liabilities as a result of the anti-dilution provisions in the warrants that may result in an adjustment to the warrant exercise price. The Company is required to revalue the derivative liability on each subsequent balance sheet date until the warrants are exercised or expire. The fair value of warrant liabilities in excess of proceeds received was $19.0 million, while the change in fair value of warrant liabilities was $9.9 million. Financing transaction costs in excess of proceeds received was $2.1 million, the loss on inducement to exercise warrants under the Company's tender offer was $1.9 million, and interest expense was $1.1 million. 2012 interest expense was primarily comprised of non-cash components including accretion of debt discounts and amortization of deferred financing costs. The $2.1 million of interest expense in 2011 was primarily comprised of non-cash components, including $1.2 million in amortization of debt discounts, $0.6 million fair value of warrants issued to investors in 2011 and amortization of deferred financing costs of $0.1 million. The Company considers various factors in the pricing models that it uses to value the warrants, including its current stock price, the remaining life of the warrants, the volatility of market price of its common stock, and the risk free interest rate. Future changes in the
'/>"/>

SOURCE Organovo Holdings, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Organovo Holdings, Inc. announces redemption of 2.9 million outstanding warrants
2. Organovo and OHSU Knight Cancer Institute Announce Collaboration in Cancer Research
3. Market Boosted by Strong Tech Earnings: Bank of America Corp., MAP Pharmaceuticals Inc., Swingplane Ventures Inc., World Moto, Inc., Organovo Holdings, Inc.
4. Organovo Reports Q2 2012 Financial Results, Provides Business Update
5. Organovo, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Organovo Announces Two Issued Patents, First Company Patent and Key Founder Patent
7. Organovo Holdings Appoints James T. Glover to Board of Directors
8. China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2012
9. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
10. Isis Pharmaceuticals Reports Clinical Data Showing Blunting of Severe Increases in CRP Following Endotoxin Challenge With ISIS-CRP Rx
11. Addus HomeCare Reports Fourth Quarter 2012 Results Completes Sale of Home Health Assets